Neurogene (NGNE) Price & Analysis

Compare

563 Followers

NGNE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.88 - $74.49

Previous CloseN/A

Volume20.02K

Average Volume (3M)182.51K

Market Cap

$310.63M

Enterprise Value-$35.03M

Total Cash (Recent Filing)$292.60M

Total Debt (Recent Filing)$13.54M

Price to Earnings (P/E)―

Beta2.86

Next Earnings

Aug 08, 2025

EPS Estimate

-1.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.08

Shares Outstanding14,262,066

10 Day Avg. Volume114,986

30 Day Avg. Volume182,507

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.11

Enterprise Value/Revenue-37.87

Enterprise Value/Gross Profit2.36

Enterprise Value/Ebitda0.43

Forecast

1Y Price Target

$38.20

Price Target Upside78.09% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Patient Enrollment And Age AdvantageNeurogene has received clearance to enroll patients as young as three years old, vs. six years for Taysha, which would be a potential commercial advantage for Neurogene.

Trial Design And FDA AlignmentNeurogene announced pivotal trial design appears to offer a clear path to show a benefit for Rett patients treated with NGN-401.

Bears Say

Adverse Events In High DoseHigh-dose NGN-401 led to the treatment-related serious adverse event (SAE); the other high-dose patients experienced Grade 2 and 3 treatment-emergent adverse events (TEAEs) of ALT and AST elevation.

Neurogene News

NGNE Upcoming Earnings Report: What to Expect?

Neurogene Inc. (NGNE) is scheduled to report 2nd quarter earnings on 08/08/2025. Regarding Q2 estimates, Wall Street analysts...

2d ago

NGNE

Promising Prospects for Neurogene in Rett Syndrome Treatment: Buy Rating Affirmed

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on NGNE stock, giving a Buy rating yesterday....

1M ago

NGNE

Optimistic Outlook for Neurogene’s NGN-401 in Rett Syndrome Treatment Boosts Buy Rating

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Neurogene (NGNE –...

1M ago

NGNE

Neurogene’s Promising Trial Design and Safety Profile Earns Buy Rating from Analyst Mitchell Kapoor

Neurogene (NGNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

1M ago

NGNE

Promising Advancements in Neurogene’s Gene Therapy for Rett Syndrome Drive Buy Rating

William Blair analyst Sami Corwin has reiterated their bullish stance on NGNE stock, giving a Buy rating on...

1M ago

NGNE

Neurogene Announces Embolden Trial Design for Rett Syndrome

Neurogene ( ($NGNE) ) just unveiled an announcement. On June 30, 2025, Neurogene announced the design of the...

1M ago

NGNE

Neurogene says on track to share updated clinical efficacy and safety data

In addition to its update on registrational trial design for Embolden study, the company states: “Neurogene (NGNE) previously...

1M ago

NGNE

Neurogene announces registrational trial design for Embolden study of NGN-401

Neurogene (NGNE) “announced details of Embolden, the Company’s registrational clinical trial designed to evaluate NGN-401 gene therapy for...

1M ago

NGNE

Craig-Hallum bullish on Neurogene, initiates with a Buy

As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Neurogene (NGNE) with a Buy rating and $50...

2M ago

NGNE

TSHA

Neurogene initiated with a Buy at Craig-Hallum

Craig-Hallum initiated coverage of Neurogene (NGNE) with a Buy rating and $50 price target Published first on TheFly...

2M ago

NGNE

Neurogene Approves Amendments at Annual Stockholders Meeting

An update from Neurogene ( ($NGNE) ) is now available. On June 12, 2025, Neurogene Inc. held its...

2M ago

NGNE

Neurogene price target raised to $26 from $22 at BMO Capital

BMO Capital raised the firm’s price target on Neurogene (NGNE) to $26 from $22 and keeps an Outperform...

2M ago

NGNE

Neurogene Highlights Gene Therapy Advancements in New Update

Neurogene ( ($NGNE) ) has provided an announcement. On June 9, 2025, Neurogene Inc. updated its corporate presentation,...

2M ago

NGNE

Neurogene Reports Q1 2025 Financial Progress and Updates

Neurogene Inc. ( ($NGNE) ) has released its Q1 earnings. Here is a breakdown of the information Neurogene...

2M ago

NGNE

NGNE FAQ

What was Neurogene’s price range in the past 12 months?

Neurogene lowest stock price was $6.88 and its highest was $74.49 in the past 12 months.

What is Neurogene’s market cap?

Neurogene’s market cap is $310.63M.

When is Neurogene’s upcoming earnings report date?

Neurogene’s upcoming earnings report date is Aug 08, 2025 which is tomorrow.

How were Neurogene’s earnings last quarter?

Neurogene released its earnings results on May 09, 2025. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$1.05 by -$0.03.

Is Neurogene overvalued?

According to Wall Street analysts Neurogene’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Neurogene pay dividends?

Neurogene does not currently pay dividends.

What is Neurogene’s EPS estimate?

Neurogene’s EPS estimate is -1.16.

How many shares outstanding does Neurogene have?

Neurogene has 14,262,066 shares outstanding.

What happened to Neurogene’s price movement after its last earnings report?

Neurogene reported an EPS of -$1.08 in its last earnings report, missing expectations of -$1.05. Following the earnings report the stock price went down -1.8%.

Which hedge fund is a major shareholder of Neurogene?

Currently, no hedge funds are holding shares in NGNE

Neurogene Stock Smart Score

Outperform

Fundamentals

Return on Equity

-34.97%

Trailing 12-Months

Asset Growth

61.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neurogene

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Neurogene (NGNE) Earnings & Revenues

Historic Earnings Reports

NGNE Stock 12 Month Forecast

Average Price Target

$38.20

▲(78.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","51":"$51","18.75":"$18.75","29.5":"$29.5","40.25":"$40.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,18.75,29.5,40.25,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.19,21.560000000000002,23.93,26.3,28.67,31.040000000000003,33.410000000000004,35.78,38.150000000000006,40.52,42.89,45.260000000000005,47.63,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.19,20.652307692307694,22.114615384615387,23.57692307692308,25.03923076923077,26.501538461538466,27.963846153846156,29.42615384615385,30.88846153846154,32.35076923076923,33.81307692307693,35.275384615384624,36.73769230769231,{"y":38.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.19,19.560000000000002,19.93,20.3,20.67,21.04,21.41,21.78,22.15,22.52,22.89,23.259999999999998,23.63,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.6,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.62,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >